Lisata Therapeutics, Inc. (LSTA)

Over the past six months, Lisata Therapeutics' stock has experienced a downward trend. As of December 17, 2025, the share price was $2.01, a decline of 22.09% from December 18, 2024. Following the announcement of its Q3 2025 earnings on November 6, 2025, LSTA shares declined by 12.3%. As of January 1st, 2026, the stock was trading at $1.86, and by January 13, 2026, it had increased to $2.16.

Lisata Therapeutics' products and services do not typically experience traditional consumer-driven demand seasonality. The demand for their drug candidates is driven by ongoing clinical trials, regulatory milestones, and the prevalence of the diseases they aim to treat.

Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing innovative therapies for advanced solid tumors and other significant diseases. Their lead product candidate, certepetide, modifies the tumor microenvironment to allow anti-cancer drugs to penetrate solid tumors more effectively. The company is developing pipelines for various indications, including pancreatic, colon, and appendiceal cancers, among others. Lisata Therapeutics also utilizes its proprietary CD34+ cell therapy technology to develop therapies for ischemia diseases.

Lisata Therapeutics is headquartered in Basking Ridge, New Jersey, United States. The company's operations extend internationally, including Australia, Ireland, Japan, the UK, and the US.

In the past year, Lisata Therapeutics has maintained a "Hold" consensus rating from Wall Street analysts, with an average rating score of 2.25. The average price target set by these analysts is $23.50. The company won the "2025 BioTech Breakthrough Award for 'Overall BioPharma Solution of the Year'".

Lisata Therapeutics, Inc. has a mix of institutional, retail, and individual investors. Institutional investors hold approximately 7.72% to 8.94% of the company's stock, while insiders hold around 7.86% to 9.10%. Public companies and individual investors own approximately 84.42%. Major institutional owners include Vanguard Group Inc, Renaissance Technologies Llc, and BlackRock, Inc. Key individual owners include Erkki Ruoslahti and David Mazzo, with David Mazzo owning the most shares among individuals.